Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beyá M, Arnan M, Tormo M, Vives S, de Llano MPQ, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Guiñon A, Salamero O, Sampol A, Merchan BM, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldés A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedéu JF, Colomer D, Brunet S, Sierra J, Esteve J. Bataller A, et al. Among authors: guijarro f. Blood Adv. 2022 Feb 22;6(4):1193-1206. doi: 10.1182/bloodadvances.2021005585. Blood Adv. 2022. PMID: 34911079 Free PMC article.
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Bataller A, Oñate G, Diaz-Beyá M, Guijarro F, Garrido A, Vives S, Tormo M, Arnan M, Salamero O, Sampol A, Coll R, Vall-Llovera F, Oliver-Caldés A, López-Guerra M, Pratcorona M, Zamora L, Villamon E, Roué G, Blanco A, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM). Bataller A, et al. Among authors: guijarro f. Br J Haematol. 2020 Oct;191(1):52-61. doi: 10.1111/bjh.16857. Epub 2020 Jun 8. Br J Haematol. 2020. PMID: 32510599 Free article. Clinical Trial.
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Kayser S, Hills RK, Langova R, Kramer M, Guijarro F, Sustkova Z, Estey EH, Shaw CM, Ráčil Z, Mayer J, Zak P, Baer MR, Brunner AM, Szotkowski T, Cetkovsky P, Grimwade D, Walter RB, Burnett AK, Ho AD, Ehninger G, Müller-Tidow C, Platzbecker U, Thiede C, Röllig C, Schulz A, Warsow G, Brors B, Esteve J, Russell NH, Schlenk RF, Levis MJ. Kayser S, et al. Among authors: guijarro f. Br J Haematol. 2021 Mar;192(5):832-842. doi: 10.1111/bjh.17336. Epub 2021 Feb 2. Br J Haematol. 2021. PMID: 33529373
KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints.
Bataller A, Guijarro F, Caye-Eude A, Strullu M, Sterin A, Molina O, Chevallier P, Zaliova M, Zuna J, Mozas P, Magnano L, Grardel N, Cornillet-Lefebvre P, Fu JF, Shih LY, Boneva T, Nacheva E, Beà S, López-Guerra M, Bueno C, Menéndez P, Esteve J, Larghero P, Meyer C, Marschalek R. Bataller A, et al. Among authors: guijarro f. Blood Adv. 2021 Dec 28;5(24):5617-5620. doi: 10.1182/bloodadvances.2021005736. Blood Adv. 2021. PMID: 34638131 Free PMC article. No abstract available.
Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan.
Guijarro F, Bataller A, Diaz-Beyá M, Garrido A, Coll-Ferrà C, Vives S, Salamero O, Valcárcel D, Tormo M, Arnan M, Sampol A, Castaño-Díez S, Martínez C, Suárez-Lledó M, Fernández-Avilés F, Hernández-Boluda JC, Ribera JM, Rovira M, Brunet S, Sierra J, Esteve J. Guijarro F, et al. Bone Marrow Transplant. 2022 Aug;57(8):1304-1312. doi: 10.1038/s41409-022-01703-9. Epub 2022 May 28. Bone Marrow Transplant. 2022. PMID: 35643942
Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.
Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, Bataller A, Charry P, Esteban D, Guijarro F, Jiménez-Vicente C, Castillo-Girón C, Cortes A, Martínez-Roca A, Triguero A, Álamo JR, Beà S, Costa D, Colomer D, Rozman M, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: guijarro f. Cancers (Basel). 2022 Aug 25;14(17):4107. doi: 10.3390/cancers14174107. Cancers (Basel). 2022. PMID: 36077644 Free PMC article.
36 results